Okechukwu A. Ibeanu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Okechukwu A. Ibeanu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Dane Sandquist
Johns Hopkins University
1 shared publicationJavier Perez
Johns Hopkins University
1 shared publicationKerri Santiago
Johns Hopkins University
1 shared publicationRalph R. Chesson
Johns Hopkins University
1 shared publicationTeresa P. Díaz-Montes
Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, The Kelly Gynecologic Oncology Service, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
1 shared publicationThomas E. Nolan
Johns Hopkins University
1 shared publication
Latest Publications
- 6 August 2021
- Published by Springer Nature
- p. 643-654
Germ Cell Tumours of the Ovary
- Open Access
- 20 February 2013
- Published by Hindawi Limited in Pathology Research International
- Vol. 2013, 1-5
Outcomes in Ovarian Cancer among Hispanic Women Living in the United States: A Population-Based Analysis
Introduction. Ovarian cancer is the deadliest gynecologic cancer in the United States. There is limited data on presentation and outcomes among Hispanic women with ovarian cancer. Objective. To investigate how ovarian cancer presents among Hispanic women in the USA and to analyze differences in presentation, staging, and survival between Hispanic and non-Hispanic women with ovarian cancer. Methods. Data from January 1, 2000 to December 31, 2004 were extracted from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database. Results. The study sample comprised 1215 Hispanics (10%), 10 652 non-Hispanic whites (83%), and 905 non-Hispanic blacks (7%). Hispanic women were diagnosed with ovarian cancer at a younger age and earlier stage when compared to non-Hispanic whites, non-Hispanic blacks; . Similar proportion of Hispanics (33%), non-Hispanic whites (32%), and non-Hispanic blacks (24%) underwent lymphadenectomy; . Hispanics with epithelial ovarian cancer histology had longer five-year survival of 30.6 months compared to non-Hispanic whites (22.8 months) and non-Hispanic blacks (23.3 months); . Conclusion. Hispanic women with ovarian cancer have a statistically significantly longer median survival compared to whites and blacks. This survival difference was most apparent in patients with epithelial cancers and patients with stage IV disease.
- 20 February 2013
- Published by Hindawi Limited in Pathology Research International
- Vol. 2013, 1-5
Open AccessOutcomes in Ovarian Cancer among Hispanic Women Living in the United States: A Population-Based Analysis
Introduction. Ovarian cancer is the deadliest gynecologic cancer in the United States. There is limited data on presentation and outcomes among Hispanic women with ovarian cancer. Objective. To investigate how ovarian cancer presents among Hispanic women in the USA and to analyze differences in presentation, staging, and survival between Hispanic and non-Hispanic women with ovarian cancer. Methods. Data from January 1, 2000 to December 31, 2004 were extracted from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database. Results. The study sample comprised 1215 Hispanics (10%), 10 652 non-Hispanic whites (83%), and 905 non-Hispanic blacks (7%). Hispanic women were diagnosed with ovarian cancer at a younger age and earlier stage when compared to non-Hispanic whites, non-Hispanic blacks; . Similar proportion of Hispanics (33%), non-Hispanic whites (32%), and non-Hispanic blacks (24%) underwent lymphadenectomy; . Hispanics with epithelial ovarian cancer histology had longer five-year survival of 30.6 months compared to non-Hispanic whites (22.8 months) and non-Hispanic blacks (23.3 months); . Conclusion. Hispanic women with ovarian cancer have a statistically significantly longer median survival compared to whites and blacks. This survival difference was most apparent in patients with epithelial cancers and patients with stage IV disease.
- 1 February 2011
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 11 (3) , 295-306
Molecular pathogenesis of cervical cancer
Introduction: Cervical cancer is a sexually transmitted disease that results from infection with oncogenic types of human papillomavirus (HPV). Oncogenic HPV DNA is found in over 95% of invasive cervical cancers worldwide. Cervical cancer is a leading cause of cancer deaths in developing countries because of high HPV infection rates and lack of comprehensive cervical Pap smear testing of susceptible women. Vaccination against HPV prevents the acquisition of cervical dysplastic lesions among eligible women who have not already acquired the vaccine-specific HPV types. Methods: Literature review of the epidemiology, infection cycle, viral gene function and current vaccines related to the oncogenic types of the human papillomavirus (HPV). Conclusion: Enhanced understanding of HPV and population-based measures offer the best hope of limiting worldwide mortality due to cervical cancer. The development of therapeutic cervical cancer vaccines and/or virus-targeted drug therapies would be a giant step forward.
- 1 February 2011
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 11 (3) , 295-306
Molecular pathogenesis of cervical cancer
Introduction: Cervical cancer is a sexually transmitted disease that results from infection with oncogenic types of human papillomavirus (HPV). Oncogenic HPV DNA is found in over 95% of invasive cervical cancers worldwide. Cervical cancer is a leading cause of cancer deaths in developing countries because of high HPV infection rates and lack of comprehensive cervical Pap smear testing of susceptible women. Vaccination against HPV prevents the acquisition of cervical dysplastic lesions among eligible women who have not already acquired the vaccine-specific HPV types. Methods: Literature review of the epidemiology, infection cycle, viral gene function and current vaccines related to the oncogenic types of the human papillomavirus (HPV). Conclusion: Enhanced understanding of HPV and population-based measures offer the best hope of limiting worldwide mortality due to cervical cancer. The development of therapeutic cervical cancer vaccines and/or virus-targeted drug therapies would be a giant step forward.
- 24 March 2010
- Published by Springer Nature in International Urogynecology Journal
- Vol. 21 (8) , 995-1000
Hypertrophic cervical elongation: clinical and histological correlations
The objective of this study is to define the diagnosis of hypertrophic cervical elongation clinically and to perform histochemical and histological evaluations of patients with and without hypertrophic cervical elongation.
- 24 March 2010
- Published by Springer Nature in International Urogynecology Journal
- Vol. 21 (8) , 995-1000
Hypertrophic cervical elongation: clinical and histological correlations
The objective of this study is to define the diagnosis of hypertrophic cervical elongation clinically and to perform histochemical and histological evaluations of patients with and without hypertrophic cervical elongation.